Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) saw a significant decrease in short interest in July. As of July 15th, there was short interest totalling 360,500 shares, a decrease of 15.6% from the June 30th total of 427,100 shares. Currently, 2.1% of the shares of the company are short sold. Based on an average trading volume of 1,840,000 shares, the short-interest ratio is currently 0.2 days.
Several brokerages have recently weighed in on NAVB. HC Wainwright increased their target price on shares of Navidea Biopharmaceuticals from $4.00 to $6.00 and gave the stock a “buy” rating in a research note on Friday, May 22nd. Zacks Investment Research raised shares of Navidea Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, July 23rd. Finally, Maxim Group started coverage on shares of Navidea Biopharmaceuticals in a report on Tuesday, June 16th. They set a “buy” rating and a $4.00 price target for the company.
Shares of NAVB opened at $4.78 on Friday. Navidea Biopharmaceuticals has a fifty-two week low of $0.49 and a fifty-two week high of $5.36.
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last released its earnings results on Thursday, May 14th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter. The firm had revenue of $0.16 million for the quarter.
An institutional investor recently bought a new position in Navidea Biopharmaceuticals stock. OTA Financial Group L.P. purchased a new stake in shares of Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 65,600 shares of the biopharmaceutical company’s stock, valued at approximately $258,000. OTA Financial Group L.P. owned 0.28% of Navidea Biopharmaceuticals at the end of the most recent reporting period.
About Navidea Biopharmaceuticals
Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.
Further Reading: Limitations of the P/E Growth ratio
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.